Smith & Nephew plc ADR (SNN) — Titan Protect Analysis

SNN

Smith & Nephew plc ADR

Healthcare · ·

$30.61

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$12.7B

Total market value of the company

Trailing P/E

20.81

Premium valuation

Forward P/E

13.65

Based on estimated future earnings — lower means cheaper

Rev Growth

+7.4%

Year-over-year revenue change

Profit Margin

10.1%

How much profit the company keeps from each dollar of revenue

ROE

11.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$35.11

+15% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 5 analysts covering this stock

About Smith & Nephew plc ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization o

https://www.smith-nephew.com

Country: United Kingdom Employees: 16,988 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.514

Good returns relative to risk taken

Kelly Fraction

0.0401

Modest edge detected — smaller position warranted

Calmar Ratio

0.470

Drawdown risk outweighs the returns — higher risk profile

Annual Return

11.2%

Historical annualised return based on price data

Max Drawdown

-23.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

123

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.67

Less volatile than the market — more defensive

52W High

$38.79

21% below the year high

52W Low

$28.40

8% above the year low

Avg Volume

1,055,295

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

266.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$1.43

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

62.90

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

68.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

14.0%

Profit from core operations before interest and tax

Free Cash Flow

$877M

Positive — the business generates more cash than it spends

Revenue (TTM)

$6.2B

Total revenue over the last 12 months

Net Income

$625M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$40.00

Target Median

$35.11

Target Low

$30.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go